Genasense

Measure of Effectiveness In a company-sponsored study of 241 people, patients taking Genasense were more likely to see signs of disease totally or nearly eliminated.

FDA Cancer Czar 2008

Mr. Walker and others criticize decisions like the FDA's 2006 rejection of Genta Inc. 's drug, Genasense, for a form of leukemia.

FDA Cancer Czar 2008

Genta says it has a "compassionate use" program in the U.S. that allows patients access to its drug Genasense.

FDA Cancer Czar 2008

Patients taking Genasense didn't live longer, or show improvement in a broader measure of effectiveness, the agency said.

FDA Cancer Czar 2008

Genta shares closed the week with a massive 64% loss after an advisory panel to the U.S. Food and Drug Administration voted 7-3 against approval of the biotech firm's lead drug candidate, Genasense.

Biotech, Pharma Rallies Short-Lived 2006

Genasense (R) is being developed as an agent that may enhance the effectiveness of anticancer therapy.

TradingMarkets 2010

Ganite (R) and Genasense (R) are available on a "named-patient" basis in countries outside the United States.

TradingMarkets 2010

• Pooled results from two Phase 3 trials of Genasense confirm significance of secondary endpoints.

IBTimes.com : Top News 2010

Genasense (R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program.

TradingMarkets 2010

The Company is currently collecting long-term followup data on durable response and overall survival from the recently completed randomized Phase 3 study of Genasense (R) in patients with advanced melanoma (the AGENDA trial).

TradingMarkets 2010